However, as a proportion of total CD45 + population, G-MDSC were most decreased in the tumors and blood following combination treatment and were significantly reduced compared to untreated (p < 0.05), vehicle controls (bloods only; p < 0.01), and anti-mCTLA-4 (tumor only; p < 0.01) (Online Resource Figure S7a-b). This evidence concerns the gene PTPRC and neoplasm.